{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:25:33Z","timestamp":1791296733550,"version":"4.1.0"},"reference-count":224,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T00:00:00Z","timestamp":1393804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT0991213"],"award-info":[{"award-number":["FT0991213"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian National Health and Medical Research Council"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijpddr.2014.02.002","type":"journal-article","created":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T10:56:49Z","timestamp":1395658609000},"page":"95-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":301,"title":["Drug repurposing and human parasitic protozoan diseases"],"prefix":"10.1016","volume":"4","author":[{"given":"Katherine T.","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina S.","family":"Skinner-Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ijpddr.2014.02.002_b0005","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1475-2875-8-S1-S7","article-title":"Dispersible formulation of artemether\/lumefantrine: specifically developed for infants and young children","volume":"8","author":"Abdulla","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2875-12-11","article-title":"Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS, S\/AS02D malaria vaccine in infants living in a malaria-endemic region","volume":"12","author":"Abdulla","year":"2013","journal-title":"Malar. J."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0015","first-page":"843","article-title":"Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer","volume":"70","author":"Abeloff","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1125","first-page":"CD004932","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","volume":"1","author":"Abubakar","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-10-144","article-title":"Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria","volume":"10","author":"Achan","year":"2011","journal-title":"Malar. J."},{"issue":"20","key":"10.1016\/j.ijpddr.2014.02.002_b0030","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2334-9-195","article-title":"High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial","volume":"9","author":"Amadi","year":"2009","journal-title":"BMC Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/icb.2011.97","article-title":"HDAC inhibitors in parasitic diseases","volume":"90","author":"Andrews","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"24","key":"10.1016\/j.ijpddr.2014.02.002_b0050","first-page":"3467","article-title":"Towards histone deacetylase inhibitors as new antimalarial drugs","volume":"18","author":"Andrews","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"22","key":"10.1016\/j.ijpddr.2014.02.002_b0055","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1016\/j.bmcl.2013.09.015","article-title":"Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment","volume":"23","author":"Andrews","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/1475-2875-11-316","article-title":"The global pipeline of new medicines for the control and elimination of malaria","volume":"11","author":"Anthony","year":"2012","journal-title":"Malar. J."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.35.2.293","article-title":"Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii","volume":"35","author":"Araujo","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7481","key":"10.1016\/j.ijpddr.2014.02.002_b0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Disc."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AAC.46.5.1163-1173.2002","article-title":"Antiparasitic agent atovaquone","volume":"46","author":"Baggish","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","article-title":"Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story","volume":"29","author":"Baker","year":"2013","journal-title":"Trends Parasitol."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00365549950163626","article-title":"Risk factors for Toxoplasma infection in pregnancy: a case-control study in France","volume":"31","author":"Baril","year":"1999","journal-title":"Scand. J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2217\/fmb.11.88","article-title":"Drug resistance in human African trypanosomiasis","volume":"6","author":"Barrett","year":"2011","journal-title":"Future Microbiol."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12019-007-0013-1","article-title":"Cinchonism in a patient taking Quinine for leg cramps","volume":"33","author":"Barrocas","year":"2007","journal-title":"Compr. Ther."},{"issue":"1\u20132","key":"10.1016\/j.ijpddr.2014.02.002_b0110","first-page":"19","article-title":"Four cases of amebic liver abscess cured with chloroquine","volume":"7","author":"Basnuevo","year":"1951","journal-title":"Rev. Kuba Med. Trop. Parasitol."},{"issue":"24","key":"10.1016\/j.ijpddr.2014.02.002_b0115","first-page":"3579","article-title":"Protein kinases as potential targets for novel anti-schistosomal strategies","volume":"18","author":"Beckmann","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0125","doi-asserted-by":"crossref","first-page":"D1083","DOI":"10.1093\/nar\/gkt1031","article-title":"The ChEMBL bioactivity database: an update","volume":"42","author":"Bento","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0135","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/17425255.4.9.1209","article-title":"Treatment of leishmaniasis with miltefosine: 2008 status","volume":"4","author":"Berman","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0140","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull. World Health Organ."},{"issue":"13","key":"10.1016\/j.ijpddr.2014.02.002_b0145","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijpara.2007.05.007","article-title":"Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance","volume":"37","author":"Bernhard","year":"2007","journal-title":"Int. J. Parasitol."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0150","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/00313029500169742","article-title":"Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage","volume":"27","author":"Bird","year":"1995","journal-title":"Pathology"},{"issue":"23","key":"10.1016\/j.ijpddr.2014.02.002_b0160","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1021\/jm201148s","article-title":"Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness","volume":"54","author":"Bland","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1130","article-title":"PubChem: integrated platform of small molecules and biological activities","volume":"4","author":"Bolton","year":"2008","journal-title":"Annu. Rep. Comput. Chem."},{"issue":"4228","key":"10.1016\/j.ijpddr.2014.02.002_b1135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bmj.1.4228.76","article-title":"Sulphadiazine","volume":"1","author":"British Medical Journal","year":"1942","journal-title":"Br. Med. J."},{"issue":"5052","key":"10.1016\/j.ijpddr.2014.02.002_b1140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bmj.2.5052.1042","article-title":"TOXOPLASMIC uveitis and pyrimethamine (author not listed)","volume":"2","author":"British Medical Journal","year":"1957","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2008.06.005","article-title":"Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection","volume":"378","author":"Brouwers","year":"2008","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0185","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1365-3156.2001.00775.x","article-title":"The phenomenon of treatment failures in Human African Trypanosomiasis","volume":"6","author":"Brun","year":"2001","journal-title":"Trop. Med. Int. Health"},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/fmb.11.44","article-title":"Development of novel drugs for human African trypanosomiasis","volume":"6","author":"Brun","year":"2011","journal-title":"Future Microbiol."},{"issue":"Supp 1","key":"10.1016\/j.ijpddr.2014.02.002_b0195","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0200","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-3156.2001.00725.x","article-title":"Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment","volume":"6","author":"Burri","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpddr.2014.02.002_b0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar. J."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0210","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2008.11.029","article-title":"Mebendazole in parasitic infections other than those caused by soil-transmitted helminths","volume":"103","author":"Canete","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"15","key":"10.1016\/j.ijpddr.2014.02.002_b0215","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1021\/jm900187v","article-title":"Recent advances in the development of polyamine analogues as antitumor agents","volume":"52","author":"Casero","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0220","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2334-8-16","article-title":"Estimates of the duration of the early and late stage of gambiense sleeping sickness","volume":"8","author":"Checchi","year":"2008","journal-title":"BMC Infect. Dis."},{"issue":"22","key":"10.1016\/j.ijpddr.2014.02.002_b0230","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMra013170","article-title":"Cryptosporidiosis","volume":"346","author":"Chen","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0235","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"Chong","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0240","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/archderm.1975.01630200057005","article-title":"Clindamycin vs placebo as adjunctive therapy in moderately severe acne","volume":"111","author":"Christian","year":"1975","journal-title":"Arch. Dermatol."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0245","first-page":"238","article-title":"Antimalarial effects of tetracyclines in man","volume":"74","author":"Clyde","year":"1971","journal-title":"J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0250","first-page":"35","article-title":"Comparison of metronidazole and chloroquine for the treatment of amoebic liver abscess","volume":"69","author":"Cohen","year":"1975","journal-title":"Control. Trial Gastroenterol."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0255","first-page":"505","article-title":"The local treatment of burns with sulfadiazine spray","volume":"47","author":"Coloviras","year":"1942","journal-title":"Can. Med. Assoc. J."},{"issue":"7254","key":"10.1016\/j.ijpddr.2014.02.002_b0260","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bmj.321.7254.142","article-title":"Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European research network on congenital toxoplasmosis","volume":"321","author":"Cook","year":"2000","journal-title":"BMJ"},{"issue":"7301","key":"10.1016\/j.ijpddr.2014.02.002_b0265","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/nature09221","article-title":"Chagas disease: a new worldwide challenge","volume":"465","author":"Coura","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/S0037-86821997000200009","article-title":"Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas\u2019 disease, in a field area with interrupted transmission. I. Preliminary evaluation","volume":"30","author":"Coura","year":"1997","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"Suppl. B","key":"10.1016\/j.ijpddr.2014.02.002_b0275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/22.Supplement_B.193","article-title":"Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection","volume":"22","author":"Couvreur","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0280","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis \u2013 current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0285","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0166-6851(02)00283-9","article-title":"Antiprotozoal activities of phospholipid analogues","volume":"126","author":"Croft","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0290","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/infdis\/jis184","article-title":"Drug screen targeted at plasmodium liver stages identifies a potent multistage antimalarial drug","volume":"205","author":"da Cruz","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-116-1-33","article-title":"Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group","volume":"116","author":"Dannemann","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0300","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir857","article-title":"Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets","volume":"206","author":"de Koning","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0310","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.ijpddr.2014.02.002_b0315","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1073\/pnas.1118370109","article-title":"Liver-stage malaria parasites vulnerable to diverse chemical scaffolds","volume":"109","author":"Derbyshire","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl. B","key":"10.1016\/j.ijpddr.2014.02.002_b0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/22.Supplement_B.207","article-title":"Spiramycin: safety in man","volume":"22","author":"Descotes","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"issue":"20","key":"10.1016\/j.ijpddr.2014.02.002_b0325","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM197405162902003","article-title":"Congenital toxoplasmosis. A prospective study of 378 pregnancies","volume":"290","author":"Desmonts","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0330","first-page":"146","article-title":"Toxoplasmosis in pregnancy and its transmission to the fetus","volume":"50","author":"Desmonts","year":"1974","journal-title":"Bull. N.Y. Acad. Med."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0335","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/cancers5031163","article-title":"Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?","volume":"5","author":"Di Santo","year":"2013","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.1976.25.14","article-title":"Single-dose therapy of Falciparum malaria using pyrimethamine in combination with diformyldapsone or sulfadoxine","volume":"25","author":"Doberstyn","year":"1976","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0345","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pt.2013.05.005","article-title":"Artemisinin resistance is a clear and present danger","volume":"29","author":"Dondorp","year":"2013","journal-title":"Trends Parasitol."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0350","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0355","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0360","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0707305","article-title":"In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling","volume":"152","author":"Ekins","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0370","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0375","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1128\/AAC.01777-09","article-title":"Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas\u2019 disease","volume":"54","author":"Engel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0380","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1535-7163.MCT-12-1243","article-title":"A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide","volume":"12","author":"Fan-Minogue","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"8790","key":"10.1016\/j.ijpddr.2014.02.002_b0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0140-6736(92)90132-M","article-title":"Azithromycin for cerebral toxoplasmosis","volume":"339","author":"Farthing","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2014.02.002_b0390","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2334-2-11","article-title":"Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study","volume":"2","author":"Flegr","year":"2002","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0395","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2334-9-72","article-title":"Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study","volume":"9","author":"Flegr","year":"2009","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4269\/ajtmh.1949.s1-29.173","article-title":"Mel B in the treatment of human trypanosomiasis","volume":"29","author":"Friedheim","year":"1949","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"7296","key":"10.1016\/j.ijpddr.2014.02.002_b0405","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nature09107","article-title":"Thousands of chemical starting points for antimalarial lead identification","volume":"465","author":"Gamo","year":"2010","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.ijpddr.2014.02.002_b0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.actatropica.2009.07.019","article-title":"Chagas disease in Spain, the United States and other non-endemic countries","volume":"115","author":"Gascon","year":"2010","journal-title":"Acta Trop."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0415","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003495-199448020-00005","article-title":"Management of toxoplasmosis","volume":"48","author":"Georgiev","year":"1994","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0420","first-page":"893","article-title":"Drug therapy reviews: trimethoprim\u2013sulfamethoxazole","volume":"36","author":"Gleckman","year":"1979","journal-title":"Am. J. Hosp. Pharm."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0425","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/sextrans-2013-051032","article-title":"Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates","volume":"89","author":"Goodhew","year":"2013","journal-title":"Sex. Transm. Infect."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/13550280802282934","article-title":"Traversal of human and animal trypanosomes across the blood\u2013brain barrier","volume":"14","author":"Grab","year":"2008","journal-title":"J. Neurovirol."},{"issue":"26","key":"10.1016\/j.ijpddr.2014.02.002_b0435","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJM199406303302604","article-title":"Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The new England regional Toxoplasma working group","volume":"330","author":"Guerina","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0440","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4269\/ajtmh.1999.61.707","article-title":"Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four\u2013seven years later in a poor urban community in northeast Brazil","volume":"61","author":"Guerrant","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0445","doi-asserted-by":"crossref","DOI":"10.1021\/jm400418p","article-title":"A class of sulfonamides with strong inhibitory action against the alpha-carbonic anhydrase from Trypanosoma cruzi","author":"Guzel-Akdemir","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1185\/030079901750176735","article-title":"Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair","volume":"16","author":"Hickman","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl. 4","key":"10.1016\/j.ijpddr.2014.02.002_b0455","doi-asserted-by":"crossref","first-page":"D104","DOI":"10.1016\/j.vaccine.2011.06.024","article-title":"Enlarging the \u201cAudacious Goal\u201d: elimination of the world\u2019s high prevalence neglected tropical diseases","volume":"29","author":"Hotez","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0460","doi-asserted-by":"crossref","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0465","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.103.055541","article-title":"Identification of novel isoform-selective inhibitors within class I histone deacetylases","volume":"307","author":"Hu","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"80","key":"10.1016\/j.ijpddr.2014.02.002_b1145","doi-asserted-by":"crossref","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0475","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.41.9.1922","article-title":"Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to d,l-alpha-difluoromethylornithine","volume":"41","author":"Iten","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5733","key":"10.1016\/j.ijpddr.2014.02.002_b0480","first-page":"436","article-title":"The genome of the kinetoplastid parasite","volume":"309","author":"Ivens","year":"2005","journal-title":"Leishmania Major Sci."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0485","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/656917","article-title":"Tolerance and safety of nifurtimox in patients with chronic chagas disease","volume":"51","author":"Jackson","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0490","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1371\/journal.pntd.0001221","article-title":"Innovative partnerships for drug discovery against neglected diseases","volume":"5","author":"Jakobsen","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0495","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/17460441.2013.783816","article-title":"Whole-organism high-throughput screening against Trypanosoma brucei brucei","volume":"8","author":"Jones","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0500","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a008942","article-title":"Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway","volume":"144","author":"Kapperud","year":"1996","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0505","doi-asserted-by":"crossref","first-page":"e56150","DOI":"10.1371\/journal.pone.0056150","article-title":"Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds","volume":"8","author":"Katiyar","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijpddr.2014.02.002_b0510","first-page":"684","article-title":"A study of experimental cutaneous leishmaniasis in white mice","volume":"30","author":"Kellina","year":"1961","journal-title":"Med. Parazitol. (Mosk)."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0515","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.bmcl.2012.01.072","article-title":"Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei","volume":"22","author":"Kelly","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0520","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness)","volume":"64","author":"Kennedy","year":"2008","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0525","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"issue":"4703","key":"10.1016\/j.ijpddr.2014.02.002_b0530","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (artemisinin): an antimalarial drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"issue":"9888","key":"10.1016\/j.ijpddr.2014.02.002_b0535","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0540","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","article-title":"Artemisinins: their growing importance in medicine","volume":"29","author":"Krishna","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0545","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bmc.2004.10.015","article-title":"Carbonic anhydrase inhibitors. Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?","volume":"13","author":"Krungkrai","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"20","key":"10.1016\/j.ijpddr.2014.02.002_b0550","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.bmcl.2008.09.030","article-title":"Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic\/heterocyclic sulfonamides-in vitro and in vivo studies","volume":"18","author":"Krungkrai","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0555","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1473-3099(13)70002-1","article-title":"Global economic burden of Chagas disease: a computational simulation model","volume":"13","author":"Lee","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0560","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0002-9343(88)90014-9","article-title":"Treatment of central nervous system toxoplasmosis with pyrimethamine\/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy","volume":"84","author":"Leport","year":"1988","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0565","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1086\/314896","article-title":"Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani","volume":"180","author":"Lira","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0570","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/00034983.1937.11684999","article-title":"Studies in chemotherapy. XVI. The trypanocidal action of synthalin","volume":"31","author":"Lourie","year":"1937","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"9859","key":"10.1016\/j.ijpddr.2014.02.002_b0575","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ijpddr.2014.02.002_b0580","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4155\/fmc.12.183","article-title":"Plasmodium kinases as targets for new-generation antimalarials","volume":"4","author":"Lucet","year":"2012","journal-title":"Future Med. Chem."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0585","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/clinids\/15.2.211","article-title":"Toxoplasmic encephalitis in AIDS","volume":"15","author":"Luft","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0590","first-page":"CD006201","article-title":"Chemotherapy for second-stage human African trypanosomiasis","volume":"6","author":"Lutje","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0595","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s004360050232","article-title":"Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes","volume":"83","author":"Maarouf","year":"1997","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0600","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1747-0285.2006.00389.x","article-title":"Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei","volume":"67","author":"Mackey","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"Database issue","key":"10.1016\/j.ijpddr.2014.02.002_b0605","doi-asserted-by":"crossref","first-page":"D1118","DOI":"10.1093\/nar\/gkr1053","article-title":"TDR Targets: a chemogenomics resource for neglected diseases","volume":"40","author":"Magarinos","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0610","doi-asserted-by":"crossref","first-page":"e56916","DOI":"10.1371\/journal.pone.0056916","article-title":"Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review","volume":"8","author":"Manyando","year":"2013","journal-title":"PLoS ONE"},{"issue":"41","key":"10.1016\/j.ijpddr.2014.02.002_b0615","doi-asserted-by":"crossref","first-page":"39839","DOI":"10.1074\/jbc.M301625200","article-title":"Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum","volume":"278","author":"Merckx","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0620","article-title":"Combination therapy with nitazoxanide and amphotericin B, Glucantime, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes","author":"Mesquita","year":"2013","journal-title":"Acta Trop."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0625","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of Am Bisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0630","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4269\/ajtmh.1974.23.565","article-title":"Evaluation of clindamycin in combination with quinine against multidrug-resistant strains of Plasmodium falciparum","volume":"23","author":"Miller","year":"1974","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0635","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.01544-06","article-title":"Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth","volume":"51","author":"Mishina","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0640","first-page":"37","article-title":"Clinical trial of nifurtimox in human African trypanosomiasis","volume":"64","author":"Moens","year":"1984","journal-title":"Ann. Soc. Belg. Med. Trop."},{"issue":"9425","key":"10.1016\/j.ijpddr.2014.02.002_b0645","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0650","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd3473","article-title":"Could pharma open its drug freezers?","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0655","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrd3776","article-title":"Drug repurposing programmes get lift off","volume":"11","author":"Mullard","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0660","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exppara.2007.06.008","article-title":"Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides","volume":"118","author":"Muller","year":"2008","journal-title":"Exp. Parasitol."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0665","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/ijc.23755","article-title":"Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells","volume":"123","author":"Muller","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0670","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1128\/AAC.00227-13","article-title":"Evaluation of nifurtimox treatment of chronic chagas disease by means of several parasitological methods","volume":"57","author":"Munoz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9894","key":"10.1016\/j.ijpddr.2014.02.002_b0675","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(13)60889-2","article-title":"Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment","volume":"382","author":"Murphy","year":"2013","journal-title":"Lancet"},{"issue":"9814","key":"10.1016\/j.ijpddr.2014.02.002_b0680","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","article-title":"Global malaria mortality between 1980 and 2010: a systematic analysis","volume":"379","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.ijpddr.2014.02.002_b0685","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0690","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0166-6851(98)00037-1","article-title":"Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox","volume":"93","author":"Murta","year":"1998","journal-title":"Mol. Biochem. Parasitol."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0695","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccc.2013.03.005","article-title":"Infections of the developing world","volume":"29","author":"Murthy","year":"2013","journal-title":"Crit. Care Clin."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0700","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/infdis\/165.3.528","article-title":"Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala","volume":"165","author":"Navin","year":"1992","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0705","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/00034983.1968.11686529","article-title":"The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis","volume":"62","author":"Neal","year":"1968","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0710","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jac\/35.5.577","article-title":"The sensitivity of Leishmania species to aminosidine","volume":"35","author":"Neal","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b1150","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI27798.","article-title":"Blood\u2013brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease","volume":"116","author":"Nikolskaia","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0720","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543776.2012.724063","article-title":"Artemisinin derivatives: a patent review (2006 \u2013 present)","volume":"22","author":"Njuguna","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0725","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jacc.2013.05.046","article-title":"Chagas disease: an overview of clinical and epidemiological aspects","volume":"62","author":"Nunes","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0730","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","article-title":"Innovative lead discovery strategies for tropical diseases","volume":"5","author":"Nwaka","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.ijpddr.2014.02.002_b0735","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/17425255.2013.834046","article-title":"Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data","volume":"9","author":"O\u2019Brien","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0740","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ejmech.2012.07.038","article-title":"The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing","volume":"62","author":"Ochiana","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0745","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.spid.2004.07.003","article-title":"Management of children with infection-associated persistent diarrhea","volume":"15","author":"Ochoa","year":"2004","journal-title":"Semin. Pediatr. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0750","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14656566.2013.771167","article-title":"Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa","volume":"14","author":"Ogutu","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0755","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0760","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-4362.1997.00022.x","article-title":"A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey","volume":"36","author":"Ozgoztasi","year":"1997","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0765","unstructured":"Paladin Labs Inc, 2010. Application for Inclusion of Miltefosine on WHO. Model List of Essential Medicines."},{"issue":"8","key":"10.1016\/j.ijpddr.2014.02.002_b0770","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.seizure.2007.05.010","article-title":"Meta-analysis of three case controlled studies and an ecological study into the link between cryptogenic epilepsy and chronic toxoplasmosis infection","volume":"16","author":"Palmer","year":"2007","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0775","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/jm4000616","article-title":"Cloning, characterization, and sulfonamide and thiol inhibition studies of an alpha-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease","volume":"56","author":"Pan","year":"2013","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0780","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1021\/jm400349k","article-title":"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis","volume":"56","author":"Patel","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0785","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1378\/chest.101.1.67","article-title":"Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome","volume":"101","author":"Paulson","year":"1992","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0790","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis","volume":"33","author":"Pepin","year":"1994","journal-title":"Adv. Parasitol."},{"issue":"8573","key":"10.1016\/j.ijpddr.2014.02.002_b0800","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(87)91131-7","article-title":"Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness","volume":"2","author":"Pepin","year":"1987","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b0805","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd1824","article-title":"Opportunities and challenges in antiparasitic drug discovery","volume":"4","author":"Pink","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0810","doi-asserted-by":"crossref","first-page":"e64450","DOI":"10.1371\/journal.pone.0064450","article-title":"Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease","volume":"8","author":"Pinto","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0815","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.2012.12-0022","article-title":"In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis\u2013status of newly introduced drugs","volume":"87","author":"Prajapati","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0820","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox\u2013eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"9683","key":"10.1016\/j.ijpddr.2014.02.002_b0825","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox\u2013eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0830","first-page":"404","article-title":"Incidence of anemia in leprosy patients treated with dapsone","volume":"67","author":"Puavilai","year":"1984","journal-title":"J. Med. Assoc. Thai."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0835","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14756360410001689577","article-title":"Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy","volume":"19","author":"Reungprapavut","year":"2004","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0840","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4269\/ajtmh.1971.20.811","article-title":"Effects of tetracycline against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum","volume":"20","author":"Rieckmann","year":"1971","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0845","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0035-9203(03)90167-2","article-title":"Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b0850","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1406.071266","article-title":"High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo","volume":"14","author":"Robays","year":"2008","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0855","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","author":"Robert-Gangneux","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0860","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201300172","article-title":"Synthesis and anti-plasmodium activity of benzimidazole analogues structurally related to astemizole","author":"Roman","year":"2013","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0865","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.reprotox.2005.10.006","article-title":"Congenital toxoplasmosis\u2013prenatal aspects of Toxoplasma gondii infection","volume":"21","author":"Rorman","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0870","article-title":"Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds","author":"Sateriale","year":"2013","journal-title":"J. Am. Med. Inform. Assoc."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0875","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.mph.0000212994.56812.f2","article-title":"Antitumor activity of nifurtimox observed in a patient with neuroblastoma","volume":"28","author":"Saulnier Sholler","year":"2006","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0880","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MPH.0b013e3181f47061","article-title":"A phase 1 study of nifurtimox in patients with relapsed\/refractory neuroblastoma","volume":"33","author":"Saulnier Sholler","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0885","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00126334-200403010-00002","article-title":"Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors","volume":"35","author":"Savarino","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ijpddr.2014.02.002_b0890","first-page":"162","article-title":"Treatment of amoebic hepatitis with emetine and chloroquine","volume":"1","author":"Scaffidi","year":"1959","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0895","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijantimicag.2010.03.008","article-title":"Efficacy of artemisinin in experimental visceral leishmaniasis","volume":"36","author":"Sen","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0900","first-page":"1","article-title":"Vaniqa\u2013eflornithine 13.9% cream","volume":"6","author":"Shapiro","year":"2001","journal-title":"Skin Therapy Lett."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0905","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1371\/journal.pntd.0001007","article-title":"The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000\u20132009: the way forward","volume":"5","author":"Simarro","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0910","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro","year":"2012","journal-title":"Parasitology"},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0915","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0035-9203(97)90035-3","article-title":"The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro","volume":"91","author":"Skinner-Adams","year":"1997","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0920","first-page":"72","article-title":"The sulfonamide group as a structural alert: A distorted story?","volume":"11","author":"Smith","year":"2008","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0925","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001813-200011000-00006","article-title":"Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients","volume":"11","author":"Smorenburg","year":"2000","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b0930","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3855\/jidc.360","article-title":"Cryptosporidiosis in developing countries","volume":"1","author":"Snelling","year":"2007","journal-title":"J. Infect. Dev. Ctries."},{"issue":"5","key":"10.1016\/j.ijpddr.2014.02.002_b0935","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","article-title":"Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Sotelo","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0940","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-3305-3-15","article-title":"The development of drugs for treatment of sleeping sickness: a historical review","volume":"3","author":"Steverding","year":"2010","journal-title":"Parasit. Vectors"},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b0945","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0950","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J. Global Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b0955","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14656566.2013.755515","article-title":"Leishmaniasis: an update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0960","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b0965","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138161208783877910","article-title":"Carbonic anhydrases as drug targets","volume":"14","author":"Supuran","year":"2008","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.ijpddr.2014.02.002_b0970","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.ijpddr.2014.02.002_b0975","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.bmcl.2010.05.009","article-title":"Carbonic anhydrase inhibitors","volume":"20","author":"Supuran","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ijpddr.2014.02.002_b0980","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1086\/652240","article-title":"Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally","volume":"201","author":"Sutherland","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"18","key":"10.1016\/j.ijpddr.2014.02.002_b0985","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1021\/jm400939k","article-title":"Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis","volume":"56","author":"Syrjanen","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ijpddr.2014.02.002_b0990","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4269\/ajtmh.2011.10-0285","article-title":"Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis","volume":"84","author":"Tan","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"7516","key":"10.1016\/j.ijpddr.2014.02.002_b0995","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.331.7516.572","article-title":"Open label extension studies: research or marketing?","volume":"331","author":"Taylor","year":"2005","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b1000","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0035-9203(99)90037-8","article-title":"Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases","volume":"93","author":"Thakur","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b1005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2471\/BLT.12.111732","article-title":"The global burden of congenital toxoplasmosis: a systematic review","volume":"91","author":"Torgerson","year":"2013","journal-title":"Bull. World Health Organ."},{"issue":"3","key":"10.1016\/j.ijpddr.2014.02.002_b1010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/schbul\/sbl050","article-title":"Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis","volume":"33","author":"Torrey","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b1015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","article-title":"Specific chemotherapy of Chagas disease: controversies and advances","volume":"19","author":"Urbina","year":"2003","journal-title":"Trends Parasitol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijpddr.2014.02.002_b1020","first-page":"39","article-title":"Advances in sleeping sickness therapy","volume":"72","author":"Van Nieuwenhove","year":"1992","journal-title":"Ann. Soc. Belg. Med. Trop."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b1025","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.ppat.1001204","article-title":"A molecular mechanism for eflornithine resistance in African trypanosomes","volume":"6","author":"Vincent","year":"2010","journal-title":"PLoS Pathog."},{"issue":"Database issue","key":"10.1016\/j.ijpddr.2014.02.002_b1030","doi-asserted-by":"crossref","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","article-title":"PROMISCUOUS: a database for network-based drug-repositioning","volume":"39","author":"von Eichborn","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b1035","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkt978","article-title":"PubChem BioAssay: 2014 update","volume":"42","author":"Wang","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.ijpddr.2014.02.002_b1040","first-page":"1635","article-title":"Experience with nifurtimox in chronic Chagas\u2019 infection. Preliminary report","volume":"22","author":"Wegner","year":"1972","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.ijpddr.2014.02.002_b1045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1747-0285.2006.00391.x","article-title":"Searching for new antimalarial therapeutics amongst known drugs","volume":"67","author":"Weisman","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"5996","key":"10.1016\/j.ijpddr.2014.02.002_b1050","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1126\/science.1194923","article-title":"Microbiology. Is the tide turning for new malaria medicines?","volume":"329","author":"Wells","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b1055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14787210.2.1.43","article-title":"Nitazoxanide: a new broad spectrum antiparasitic agent","volume":"2","author":"White","year":"2004","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"4804","key":"10.1016\/j.ijpddr.2014.02.002_b1060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.1.4804.253","article-title":"Treatment of acute malaria with pyrimethamine","volume":"1","author":"Wilson","year":"1953","journal-title":"Br. Med. J."},{"issue":"11","key":"10.1016\/j.ijpddr.2014.02.002_b1065","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1046\/j.1365-3156.2001.00751.x","article-title":"Chlorproguanil\u2013dapsone (LAPDAP) for uncomplicated falciparum malaria","volume":"6","author":"Winstanley","year":"2001","journal-title":"Trop. Med. Int. Health"},{"issue":"Database issue","key":"10.1016\/j.ijpddr.2014.02.002_b1070","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijpddr.2014.02.002_b1075","first-page":"2","article-title":"Dapsone","volume":"8","author":"Wolf","year":"2002","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1080","unstructured":"World Health Organization, 2008. The global burden of disease: 2004 update."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1085","unstructured":"World Health Organization 2010, Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1090","unstructured":"World Health Organization, 2010a. Chagas Disease: control and elimination. World Health Assembly Report."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1095","unstructured":"World Health Organization, 2010b. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1100","unstructured":"World Health Organization, Global Health Observatory Map Gallery. Retrieved 15th November, 2013, from http:\/\/gamapserver.who.int\/mapLibrary\/."},{"key":"10.1016\/j.ijpddr.2014.02.002_b1105","unstructured":"World Health Organization, 2013. World Malaria Report 2013."},{"issue":"2\u20133","key":"10.1016\/j.ijpddr.2014.02.002_b1110","first-page":"153","article-title":"Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins","volume":"96","author":"Xiao","year":"2005","journal-title":"Acta Trop."},{"issue":"6043","key":"10.1016\/j.ijpddr.2014.02.002_b1115","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1126\/science.1205216","article-title":"Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets","volume":"333","author":"Yuan","year":"2011","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ijpddr.2014.02.002_b1120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archderm.1991.01680060108015","article-title":"Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature","volume":"127","author":"Zic","year":"1991","journal-title":"Arch. Dermatol."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320714000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320714000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:43:45Z","timestamp":1761921825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320714000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":224,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2211320714000050"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2014.02.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing and human parasitic protozoan diseases","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2014.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}